Clinical Trials Logo
  1. Home
  2. Qt Interval, Variation in
  3. NCT02217930

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

Qt Interval, Variation in Clinical Trial

Official title:
A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive- Controlled, Crossover Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

Clinical Trial Summary

The study designed to determine the effect induced by WCK 2349 on the QT interval.

The study will be conducted in two parts: 1) to determine the supratherapeutic dose; and 2) to assess the safety of high doses of single-dose administration of WCK 2349 on the QT interval.

Clinical Trial Description

Part 1 of this study will determine the supratherapeutic dose to be used in Part 2. Part 1will enroll 8 subjects at each of 4 dose levels (up to 32 subjects). Cohorts will be staggered so that appropriate safety monitoring and follow-up can be performed for each subject at each dose level.

Safety monitoring will be based upon review of AEs, ECGs and clinical laboratory test results prior to escalation to the next dose level.

At the first dose level, 6 subjects will be randomly assigned to receive a single dose of WCK 2349 at 1800 mg and 2 subjects will be randomly assigned to placebo. If this dose is tolerated by subjects, and safety data allows, the next group will be initiated in the same fashion at a dose of 2200 mg. If this dose is tolerated by subjects, and safety data allows, the next group will be initiated in the same fashion at a dose of 2600 mg. If this dose is tolerated by subjects, and safety data allows, the next group will be initiated in the same fashion at a dose of 3000 mg. Based upon safety data, the highest safely tolerated dose in Part 1 will be utilized as the supratherapeutic dose in Part 2. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02217930
Study type Interventional
Source Wockhardt
Contact
Status Completed
Phase Phase 1
Start date August 2014
Completion date July 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT02924337 - Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects Phase 1
Completed NCT02241252 - Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients N/A
Completed NCT02063620 - The Effect of Anesthetic Agents Management on ECG Changes of Patients Who Were Operated Under RIVA N/A
Completed NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Completed NCT05757063 - Impact of Two Different Types of Sedation on ICEB N/A
Completed NCT03822520 - Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib Phase 1
Not yet recruiting NCT04437901 - COVIDAR - Arrhythmias in COVID-19
Suspended NCT04005027 - Exercise Induced QT Interval Changes in Response to Intermittent and Continuous Graded Exercise Tests N/A
Completed NCT04000542 - Pharmacist Use of ECG to Inform Drug Therapy Decisions for Patients Receiving QT Prolonging Medications N/A
Recruiting NCT05488470 - QT Changes as Detected From LINQ ECG During and After Antiarrhythmic Loading (LINQ QT)
Completed NCT02492347 - Effect of Antenatal SSRI Exposure on the QT Interval of Neonates N/A
Completed NCT01365806 - Home Electrocardiogram (ECG) Monitoring After Heart Transplantation N/A
Active, not recruiting NCT03642405 - Drug-induced Repolarization ECG Changes
Completed NCT03475459 - Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7) Phase 1